Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine with or without lenalidomide in high-risk MDS/AML with del(5q)
2011-001639-21Phase 2Completed
- Sponsor
- Nordic MDS Group
- Start
- Sep 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) comparing Azacitidine alone with Azacitidine plus lenalidomide (2 arms). Primary endpoint: Response according to IWG criteria for MDS and AML. Started Sep 2011; status: completed.
02
Drugs
azacitidinelenalidomide
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2011-001639-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001639-21.